{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:08:32Z","timestamp":1788581312825,"version":"build-2803163510"},"reference-count":83,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2024,7,2]]},"DOI":"10.1080\/14728214.2024.2345645","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T08:20:41Z","timestamp":1714378841000},"page":"193-204","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Aticaprant: (a \u03ba-opioid receptor antagonist) for major depressive disorder"],"prefix":"10.1080","volume":"29","author":[{"given":"Elliot","family":"Hampsey","sequence":"first","affiliation":[{"name":"King\u2019s College London","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Jelen","sequence":"additional","affiliation":[{"name":"King\u2019s College London","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan H.","family":"Young","sequence":"additional","affiliation":[{"name":"King\u2019s College London","place":["London, UK"]},{"name":"South London & Maudsley NHS Foundation Trust","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"e_1_3_6_3_1","unstructured":"World Health Organisation. International classification of diseases eleventh revision (ICD-11). 2019."},{"key":"e_1_3_6_4_1","unstructured":"World Health Organisation. Depression and other common mental disorders: global health estimates. 2017."},{"key":"e_1_3_6_5_1","unstructured":"Office for National Statistics. Cost of living and depression in adults Great Britain: 29 September to 23 October 2022. 2022."},{"key":"e_1_3_6_6_1","unstructured":"Department for Health and Social Care. No health without mental health: a cross-government mental health outcomes strategy for people of all ages. 2011."},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2022.28"},{"key":"e_1_3_6_8_1","unstructured":"Mind. We need to talk survey [Internet]. Available from: https:\/\/www.mind.org.uk\/media-a\/4248\/we-still-need-to-talk_report.pdf."},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1719"},{"key":"e_1_3_6_10_1","unstructured":"National Institute for Health and Care Excellence. Depression in adults: treatment and management. 2022."},{"key":"e_1_3_6_11_1","unstructured":"Public Health England. Prescribed medicines review: summary. 2020."},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32802-7"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13097TX1C"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2010.06.006"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.05.048"},{"key":"e_1_3_6_16_1","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of depression. [Internet]. 2013 [cited 2023 Nov 29]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-depression_en.pdf."},{"key":"e_1_3_6_17_1","unstructured":"Global Market Insights. Antidepressant drugs market size - by drug class (SSRIs SNRIs tricyclic antidepressants) by application (Major depressive disorder obsessive-compulsive disorder generalized anxiety disorder panic disorder) competitive market share & forecast 2021 - 2027. 2021."},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1714-9097"},{"key":"e_1_3_6_19_1","unstructured":"Newswire PR. Antidepressant drugs market global analysis by drugs class by sales channel by region by country: opportunities and forecasts 2018 to 2023: inquire for antidepressant drugs market global research report 2018 with in-depth industry study analysis and forecasting till 2023. 2018."},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21056"},{"key":"e_1_3_6_21_1","unstructured":"Fava M Carpenter L Zajecka J et al. Proof-of-concept trial of CERC-501 augmentation of antidepressant therapy i n treatment-resistant depression (RAPID KOR). 2016."},{"key":"e_1_3_6_22_1","unstructured":"Janssen Research & Development LLC. A study to explore the efficacy of JNJ-67953964 in the treatment of depression. 2023."},{"key":"e_1_3_6_23_1","unstructured":"Janssen Research & Development LLC. A study of aticaprant in adult and elderly participants with Major depressive disorder (MDD) (VENTURA-LT). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05518149?term=NCT05518149&rank=1"},{"key":"e_1_3_6_24_1","unstructured":"Janssen Research & Development LLC. A study of aticaprant as adjunctive therapy in adult participants with Major depressive disorder (MDD) with moderate-to-severe anhedonia and inadequate response to Current antidepressant therapy (VENTURA-1). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05455684?term=NCT05455684&rank=1"},{"key":"e_1_3_6_25_1","unstructured":"Janssen Research & Development LLC. A study of aticaprant 10 milligrams (mg) as adjunctive therapy in adult participants with MDD with moderate-to-severe anhedonia and inadequate response to Current antidepressant therapy (VENTURA-2). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05550532?term=NCT05550532%20&rank=1"},{"key":"e_1_3_6_26_1","unstructured":"BlackThorn Therapeutics Inc. Study in Major depressive disorder with BTRX-335140 (NMRA-335140) vs placebo. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04221230?term=NCT04221230&rank=1"},{"key":"e_1_3_6_27_1","unstructured":"Neumora Therapeutics Inc. Study to evaluate the effects of oral NMRA 335140 versus placebo in participants with Major depressive disorder. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06029426?term=BTRX-335140&rank=5"},{"key":"e_1_3_6_28_1","unstructured":"Neumora Therapeutics Inc. Study to assess the safety and effectiveness of NMRA-335140-501. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06029439?term=BTRX-335140&rank=3"},{"key":"e_1_3_6_29_1","unstructured":"Alkermes Inc. ALK33BUP-201: safety and tolerability study of ALKS 33-BUP (ALKS 5461) administration in subjects with MDD. 2011. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01381107?term=ALKS-5461&page=2&rank=17"},{"key":"e_1_3_6_30_1","unstructured":"Alkermes Inc. A study of ALKS 5461 in healthy volunteers. 2014. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02068105?term=ALKS-5461&rank=6"},{"key":"e_1_3_6_31_1","unstructured":"Alkermes Inc. A long-term safety study of ALKS 5461. 2014. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02141399?term=ALKS-5461&page=2&rank=14"},{"key":"e_1_3_6_32_1","unstructured":"Alkermes Inc. A study of different titration schedules of ALKS 5461 in adults with Major depressive disorder (MDD). 2014. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02085135?term=ALKS-5461&page=2&rank=15"},{"key":"e_1_3_6_33_1","unstructured":"Alkermes Inc. A study to evaluate ALKS 5461 in subjects with Major depressive disorder (MDD). 2011. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01500200?term=NCT01500200&rank=1"},{"key":"e_1_3_6_34_1","unstructured":"Alkermes Inc. A study of ALKS 5461 for the treatment of Major depressive disorder (MDD) - the FORWARD-3 study. 2014. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02158546?term=ALKS-5461&rank=9"},{"key":"e_1_3_6_35_1","unstructured":"Alkermes Inc. A study of ALKS 5461 for the treatment of Major depressive disorder (MDD) - the FORWARD-4 study. 2014. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02158533?term=ALKS-5461&rank=7"},{"key":"e_1_3_6_36_1","unstructured":"Alkermes Inc. A study of ALKS 5461 for the treatment of Major depressive disorder (MDD) - FORWARD-5 study. 2014. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02218008?term=NCT02218008&rank=1"},{"key":"e_1_3_6_37_1","unstructured":"Alkermes Inc. A study of ALKS 5461 for treatment refractory Major depressive disorder (MDD). 2017. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03188185?term=ALKS-5461&rank=10"},{"key":"e_1_3_6_38_1","unstructured":"Alkermes Inc. A long term study of ALKS 5461 in the treatment of refractory Major depressive disorder (MDD). 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03610048?term=NCT03610048%20&rank=1"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104800"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2023_448"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15060770"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852917000074"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.12265"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000462606.17725.93"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2020.05.017"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyab050"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2014.00170"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.092304"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1680-y"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.171"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3095-8"},{"issue":"2","key":"e_1_3_6_52_1","article-title":"The effects of pentazocine, a kappa agonist, in patients with mania","volume":"11","author":"Cohen BM","year":"2008","unstructured":"Cohen BM, Murphy B. The effects of pentazocine, a kappa agonist, in patients with mania. Int J Neuropsychopharmacol [Internet]. 2008 [cited 2023 Oct 17];11(2). Available from: https:\/\/academic.oup.com\/ijnp\/article-lookup\/doi\/10.1017\/S1461145707008073","journal-title":"Int J Neuropsychopharmacol [Internet]"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2009.09.074"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010919-023317"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.04.017"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.046433"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-0167-4"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.185108"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.09.021"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01679"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.22500"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz054"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232864"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2015.05.023"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0015-y"},{"issue":"1","key":"e_1_3_6_66_1","article-title":"Aticaprant (clinically developed kappa-opioid receptor antagonist) combined with naltrexone prevents alcohol \u201crelapse\u201d drinking","volume":"9","author":"Zhou Y","year":"2022","unstructured":"Zhou Y. Aticaprant (clinically developed kappa-opioid receptor antagonist) combined with naltrexone prevents alcohol \u201crelapse\u201d drinking. J Pharm Pharmacol [Internet]. 2022 [cited 2023 Oct 17];9(1). Available from: https:\/\/www.avensonline.org\/fulltextarticles\/JPP-2327-204X-09-0032.html","journal-title":"J Pharm Pharmacol [Internet]"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108254"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05649-y"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/76061"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.2174\/157015912803217314"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2022.173341"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.02.029"},{"key":"e_1_3_6_73_1","unstructured":"AstraZeneca. Study of antidepressant efficacy of a selective high affinity enkephalinergic agonist in anxious major depressive disorder (AMDD). 2012."},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.3892\/br.2017.877"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.381368"},{"issue":"2","key":"e_1_3_6_76_1","article-title":"Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human","volume":"18","author":"Rorick-Kehn LM","year":"2015","unstructured":"Rorick-Kehn LM, Witcher JW, Lowe SL, et al. Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human. Int J Neuropsychopharmacol [Internet]. 2015 cited 2023 Oct 17; 18(2). Available from: https:\/\/academic.oup.com\/ijnp\/article-lookup\/doi\/10.1093\/ijnp\/pyu036","journal-title":"Int J Neuropsychopharmacol [Internet]"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.286"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.205"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0806-7"},{"issue":"1","key":"e_1_3_6_80_1","article-title":"Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression","volume":"33","author":"Fava M","year":"2020","unstructured":"Fava M, Mazzone E, Freeman M, et al. Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. Ann Clin Psychiatry [Internet]. 2020 [cited 2023 Oct 17];33(1). Available from: https:\/\/www.aacp.com\/article\/abstract\/double-blind-placebo-controlled-proof-of-concept-trial-of-a-kappa-selective-opioid-receptor-antagonist-augmentation-in-treatment-resistant-depression\/","journal-title":"Ann Clin Psychiatry [Internet]"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0712"},{"key":"e_1_3_6_82_1","doi-asserted-by":"crossref","unstructured":"Opioid antagonists. Meylers side eff drugs int encycl adverse drug react interact [internet]. Elsevier; 2006 [cited 2023 Oct 17]. p. 2639. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B0444510052001972","DOI":"10.1016\/B0-44-451005-2\/00197-2"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.03.040"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2017.01.015"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1459564"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2024.2345645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:43:57Z","timestamp":1738561437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2024.2345645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7,2]]}},"alternative-id":["10.1080\/14728214.2024.2345645"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2024.2345645","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}